For Medical Practitioners

Where clinical rigor
meets the frontier
of healing.

A healing center built by clinicians, for the clinical community.

The Collective is a medically owned and operated licensed psilocybin healing center — founded by a board-certified psychiatrist, two dual-certified family and psychiatric nurse practitioners, and a clinical team with deep roots in neurology, trauma, addiction, and integrative medicine. We built this because we believe the future of mental health care belongs at the intersection of evidence and experience — and we are committed to advancing both.

We welcome referrals, collaborative relationships, and conversations with medical professionals who share that conviction.

Zephyr Collective clinical team in a consultation setting

Referrals

Referring a Patient

We communicate directly with referring providers on complex presentations. You will not be left wondering what happened after you made the referral.

When you refer a patient to Zephyr Collective, they enter a program designed to the same standard of care you hold your own practice to. Every client undergoes a comprehensive medical intake before any session is scheduled — including full medication reconciliation, psychiatric history, cardiovascular screening, and cognitive assessment. For complex presentations, we communicate directly with the referring provider before proceeding.

We work with adults navigating treatment-resistant depression, anxiety, PTSD, existential distress, grief, and the psychological burden of chronic and neurological illness. We have developed specific clinical protocols for patients with Parkinson's disease, multiple sclerosis, traumatic brain injury, and other neurological conditions — populations that have historically been excluded from psychedelic research and are increasingly among those with the most to gain.

Intake includes

Full medication reconciliation

Psychiatric and trauma history

Cardiovascular screening

Cognitive assessment

Direct provider communication on complex cases

If you have a patient you believe may benefit from psilocybin-assisted therapy and you are unsure whether they are an appropriate candidate, we invite a direct provider-to-provider conversation.

Research

Our Commitment to Research

As a medically owned and operated healing center, we believe we have both an opportunity and an obligation to contribute to the growing body of evidence on psilocybin's therapeutic potential — particularly in conditions that remain understudied.

Psilocybin research to date has focused primarily on depression, anxiety in the context of life-threatening illness, and substance use disorders. These are important areas and the evidence is compelling. But the frontier of what psilocybin may offer is considerably broader — and we are positioned to help map it.

We seek to contribute to emerging research in the following areas:

Parkinson's disease

The first clinical trial of psilocybin in any neurodegenerative disease — published in Neuropsychopharmacology in 2025 — found psilocybin safe and well-tolerated in Parkinson's patients, with significant improvements in depression, anxiety, and non-motor symptoms sustained at three months and no exacerbation of psychosis or motor function. Our clinical team has developed a dedicated Parkinson's psilocybin protocol informed by this research, with specific screening criteria, dosing parameters, and outcome monitoring tailored to this population. We are among a small number of licensed healing centers in the country actively offering structured psilocybin programs for Parkinson's patients under medical supervision.

Multiple sclerosis and chronic neurological illness

The psychological burden of MS — depression, anxiety, cognitive changes, and the existential weight of living with an unpredictable, progressive disease — is profound and inadequately addressed by existing treatment models. Psilocybin's demonstrated effects on meaning-making, emotional processing, and neuroplasticity suggest significant potential in this population.

Traumatic brain injury and veteran populations

A 2025 study of veterans with TBI history found a 50% reduction in PTSD symptom scores and a 65% reduction in depression scores at four weeks following psilocybin-assisted therapy. Our Medical Director, Dr. Alessio Luinetti, MD, is a U.S. Air Force veteran and former Chief of Psychiatry Consultation at Brooke Army Medical Center.

Chronic pain and somatic illness

The relationship between psilocybin, default mode network disruption, and the psychological dimensions of chronic pain is an emerging and underexplored area of research. We are developing group and individual protocols for patients navigating chronic illness and pain, integrating psilocybin-assisted therapy with somatic awareness and integration-focused psychotherapy.

Collaboration

Research Collaboration

We are actively interested in collaborative research relationships with academic medical centers, neurology practices, psychiatry departments, and independent investigators working in psychedelic medicine.

As a licensed Colorado healing center with a medically trained founding team, we are positioned to contribute real-world clinical data, case documentation, and outcomes tracking to the growing evidence base.

"The science moves faster when clinicians work together."

If you are conducting or planning research in any of the areas above — or if you are treating patients whose presentations raise questions about psilocybin's potential role — we want to hear from you.

Natural landscape representing Zephyr Collective's connection between science and healing

Provider Programs

Healing the Healer

We also hold space for the providers themselves.

Healthcare workers carry a particular burden — the weight of other people's suffering, the erosion of idealism that comes with years inside a system not designed for the healers within it, and the isolation of being the person who holds space for everyone else. Burnout, compassion fatigue, and moral injury are not personal failings. They are the predictable result of asking more of people than any system gives back.

Several members of our founding team came to psilocybin through their own need — as clinicians, as caregivers, as people who understood what they were recommending to others and recognized they needed it themselves. We understand what it means to need this from the inside.

We offer individual journeys, group sessions, and provider-specific programs designed for healthcare professionals seeking renewal, recalibration, and reconnection with the reason they entered this work.

Individual journeys

Group sessions

Provider-specific programs

Complete confidentiality

You will be seen as a whole person — not as a clinician who should know better than to struggle.

Screening Standards

Contraindications & Screening

We apply rigorous screening standards and do not proceed with clients for whom psilocybin carries unacceptable risk. For neurologically complex referrals, we require direct communication with the managing specialist before proceeding.

Absolute contraindications

Personal or first-degree family history of schizophrenia or bipolar I disorder

Active or recent psychotic symptoms

Current use of MAOIs, lithium, or tramadol

Uncontrolled seizure disorder

Pregnancy

Significant uncontrolled cardiovascular disease

Relative contraindications

Reviewed individually on a case-by-case basis. We encourage provider-to-provider consultation for borderline or complex presentations before referral.

Protocol documentation

Full clinical contraindication criteria and our intake screening protocol are available upon request.

Request protocol

Connect With Us

Begin the conversation.

We welcome provider-to-provider conversations, referral relationships, and research collaborations. Reach out directly to the team member most relevant to your inquiry.

Annmarie Kropp, DNP, FNP-C, PMHNP-BC

Referrals & Provider Relations

annmarie@zephyr-collective.com

Emily Sisa, MSN, PMHNP-BC, FNP-C

Director of Psychedelic Programming

emily@zephyr-collective.com

Dr. Alessio Luinetti, MD

Medical Director

alessio@zephyr-collective.com